These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 19775297

  • 1. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
    Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A.
    Br J Haematol; 2009 Nov; 147(4):515-25. PubMed ID: 19775297
    [Abstract] [Full Text] [Related]

  • 2. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
    Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, Martell RE, MacBeth K, Younes A.
    Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
    [Abstract] [Full Text] [Related]

  • 3. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y.
    PLoS One; 2012 Nov; 7(12):e52095. PubMed ID: 23251689
    [Abstract] [Full Text] [Related]

  • 4. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
    Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA.
    Clin Cancer Res; 2015 Oct 15; 21(20):4663-75. PubMed ID: 26116270
    [Abstract] [Full Text] [Related]

  • 5. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y, Wallach J, Duane S, Wang Y, Wu J, Wang J, Adejare A, Ma H.
    Drug Des Devel Ther; 2017 Oct 15; 11():1369-1382. PubMed ID: 28496307
    [Abstract] [Full Text] [Related]

  • 6. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.
    Mol Cancer Ther; 2008 Apr 15; 7(4):759-68. PubMed ID: 18413790
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K.
    J Biol Chem; 2005 Jul 22; 280(29):26729-34. PubMed ID: 15937340
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
    Hackanson B, Rimmele L, Benkißer M, Abdelkarim M, Fliegauf M, Jung M, Lübbert M.
    Leuk Res; 2012 Aug 22; 36(8):1055-62. PubMed ID: 22464548
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B, Chen X, Gao J, Su L, Zhang L, Xu H, Luan Y.
    Bioorg Med Chem Lett; 2019 Sep 15; 29(18):2638-2645. PubMed ID: 31400938
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle.
    Ma XJ, Xu G, Li ZJ, Chen F, Wu D, Miao JN, Zhan Y, Fan Y.
    Curr Med Sci; 2019 Apr 15; 39(2):228-236. PubMed ID: 31016515
    [Abstract] [Full Text] [Related]

  • 13. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
    Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S.
    J Biol Chem; 2004 Feb 27; 279(9):7685-91. PubMed ID: 14670976
    [Abstract] [Full Text] [Related]

  • 14. A novel class of small molecule inhibitors of HDAC6.
    Inks ES, Josey BJ, Jesinkey SR, Chou CJ.
    ACS Chem Biol; 2012 Feb 17; 7(2):331-9. PubMed ID: 22047054
    [Abstract] [Full Text] [Related]

  • 15. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
    Noack M, Leyk J, Richter-Landsberg C.
    Glia; 2014 Apr 17; 62(4):535-47. PubMed ID: 24464872
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
    North BJ, Almeciga-Pinto I, Tamang D, Yang M, Jones SS, Quayle SN.
    PLoS One; 2017 Apr 17; 12(3):e0173507. PubMed ID: 28264055
    [Abstract] [Full Text] [Related]

  • 17. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT, Knoff JR, Pflum MKH.
    Eur J Med Chem; 2018 Jan 01; 143():1790-1806. PubMed ID: 29150330
    [Abstract] [Full Text] [Related]

  • 18. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z, Cai Y, Yang Y, Li A, Bi R, Wang L, Shen X, Wang W, Jia Y, Yu B, Cao B, Cui W, Wei P, Zhou X.
    J Pathol; 2018 Oct 01; 246(2):141-153. PubMed ID: 29876933
    [Abstract] [Full Text] [Related]

  • 19. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M.
    Blood; 2017 Oct 05; 130(14):1628-1638. PubMed ID: 28830887
    [Abstract] [Full Text] [Related]

  • 20. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y, Gómez-Vidal JA, de Pedro N, Bello M, Rosales-Hernández MC, Correa-Basurto J.
    Sci Rep; 2020 Jun 26; 10(1):10462. PubMed ID: 32591593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.